Biotech | April 20, 2026
FDA pushes forward on gene-editing therapies with new safety roadmap
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The company allocated €56 million to research and development for next-generation line solutions
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
In his new role, Karthik will lead human capital strategy and HR operations across these regions
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Subscribe To Our Newsletter & Stay Updated
